ArticleCardiovascular diabetology2020

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.